Right on. And while doing some research for a breast cancer patient friend, I was happy to see that while tumors like HER2- breast cancer are usually CCR5 negative, their mets and CTCs not uncommonly express CCR5 due to DNA plasticity. Can't wait for human results to corroborate this so we can get going. Strictly a hunch, but I think it wouldn't take much to bump us into accelerated approval status.